fashion -WSS

fashion

author：entertainment 2025-10-01 23:58:48 - browse：1184

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Prosecutors seek bail revocation for FTX founder Sam Bankman

focus

leisure time

WSS

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Head of FDA's diagnostics center, who led through Covid, retires

Climate activists disrupt London Pride march to protest corporate sponsorship

Cardiologists urge adding sexual orientation, gender identity to health records

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

The inclusion problem at the heart of rehabilitation research

leisure time

fashion

hotspot

Medical records are filled with copy

Medical schools are missing the mark on artificial intelligence

23andMe had bad news about my health. I wish a person had delivered it

Pumping milk in bathrooms at health conferences is common

Drug repurposing or repositioning? The language matters

To bolster infectious disease surveillance, genomics powerhouses team up

Dobbs anniversary: the lost opportunity of abortion as health care

Medical mystery: When an infection after surgery isn’t what it seems

What does generative AI mean for health care? We asked experts

CVS is on a mission to consolidate health care. Will it work?

hotspot

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

What causes osteoarthritis? Researchers study link to brain protein

Scientists find bacteria from stomach of ancient iceman

Microsoft launches AI tool for clinical documentation through Epic

Medicare drug price lawsuits could be good politics for Biden

FDA endorses new sterilization method for medical devices

focus

leisure time

leisure time

focus